MX2022010959A - Terapia genica para trastornos oculares. - Google Patents

Terapia genica para trastornos oculares.

Info

Publication number
MX2022010959A
MX2022010959A MX2022010959A MX2022010959A MX2022010959A MX 2022010959 A MX2022010959 A MX 2022010959A MX 2022010959 A MX2022010959 A MX 2022010959A MX 2022010959 A MX2022010959 A MX 2022010959A MX 2022010959 A MX2022010959 A MX 2022010959A
Authority
MX
Mexico
Prior art keywords
ocular disorders
adeno
nucleic acid
acid molecule
sequence encoding
Prior art date
Application number
MX2022010959A
Other languages
English (en)
Inventor
Junwei Sun
Jean Bennett
Jeannette Bennicelli
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2022010959A publication Critical patent/MX2022010959A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/04—Uses of viruses as vector in vivo
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan composiciones y métodos para tratar trastornos oculares en un sujeto; en un aspecto se proporciona un vector viral adenoasociado que incluye una molécula de ácido nucleico que comprende una secuencia que codifica CNGA3; en otro aspecto, se proporciona un vector viral adenoasociado que incluye una molécula de ácido nucleico que comprende una secuencia que codifica CNGB3; en otro aspecto se proporciona un vector viral adenoasociado que incluye una molécula de ácido nucleico que comprende una secuencia que codifica REP-1; en modalidades deseadas, el sujeto es un ser humano, gato, perro, oveja o primate no humano.
MX2022010959A 2015-12-14 2018-06-13 Terapia genica para trastornos oculares. MX2022010959A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562266789P 2015-12-14 2015-12-14

Publications (1)

Publication Number Publication Date
MX2022010959A true MX2022010959A (es) 2022-10-07

Family

ID=58455636

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018007230A MX2018007230A (es) 2015-12-14 2016-12-13 Terapia genica para trastornos oculares.
MX2022010959A MX2022010959A (es) 2015-12-14 2018-06-13 Terapia genica para trastornos oculares.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018007230A MX2018007230A (es) 2015-12-14 2016-12-13 Terapia genica para trastornos oculares.

Country Status (12)

Country Link
US (2) US11090392B2 (es)
EP (2) EP3795180B1 (es)
JP (2) JP7057281B2 (es)
KR (1) KR20180099719A (es)
CN (1) CN109069668B (es)
AU (1) AU2016370487C1 (es)
BR (1) BR112018011838A2 (es)
CA (1) CA3008264A1 (es)
ES (1) ES2826384T3 (es)
MX (2) MX2018007230A (es)
RU (1) RU2762747C2 (es)
WO (1) WO2017106202A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3795180B1 (en) * 2015-12-14 2025-11-05 The Trustees of The University of Pennsylvania Gene therapy for ocular disorders
CA3017487A1 (en) * 2016-04-08 2017-10-12 Krystal Biotech, Inc. Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
JP7165357B2 (ja) * 2016-07-26 2022-11-04 コーネル ユニヴァーシティー アルデヒドデヒドロゲナーゼ欠損症の治療のための遺伝子治療
WO2018232149A1 (en) * 2017-06-14 2018-12-20 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
SG11202009895TA (en) 2018-04-27 2020-11-27 Krystal Biotech Inc Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
US20220143217A1 (en) * 2019-03-04 2022-05-12 The Trustees Of The University Of Pennsylvania Neuroprotective gene therapy targeting the akt pathway
CN110889859A (zh) * 2019-11-11 2020-03-17 珠海上工医信科技有限公司 一种用于眼底图像血管分割的u型网络
CN115885040A (zh) * 2020-04-27 2023-03-31 宾夕法尼亚州大学信托人 可用于治疗cdkl5缺乏症（cdd）的组合物
CA3191545A1 (en) * 2020-09-02 2022-03-10 David H. Kirn Codon optimized rep1 genes and uses thereof
CA3209779A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
CA3209111A1 (en) 2021-02-26 2022-09-01 Matthias Charles Jerome HEBBEN Manufacturing and use of recombinant aav vectors
US11779660B2 (en) 2021-04-02 2023-10-10 Krystal Biotech, Inc. Viral vectors for cancer therapy
US20240335562A1 (en) * 2021-08-04 2024-10-10 Alpine Biotherapeutics Corporation Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
DE69824859T2 (de) 1997-04-14 2005-08-04 Cell Genesys, Inc., Foster City Methoden zur erhöhung der effizienz rekombinanter aav produkte
EP1080218A1 (en) 1998-05-27 2001-03-07 University of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
DE69941905D1 (de) 1998-11-10 2010-02-25 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
ES2308989T3 (es) 1999-08-09 2008-12-16 Targeted Genetics Corporation Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
EP1286703B1 (en) 2000-06-01 2009-08-05 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
JP2005500008A (ja) 2001-01-19 2005-01-06 インサイト・ゲノミックス・インコーポレイテッド 受容体および膜結合タンパク質
WO2002082904A2 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
NZ618298A (en) 2001-11-13 2015-04-24 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
PT2359869T (pt) 2001-12-17 2019-04-16 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
WO2003104413A2 (en) 2002-06-05 2003-12-18 University Of Florida Production of pseudotyped recombinant aav virions
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
EP2292780B1 (en) 2003-09-30 2017-08-23 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
EP2359865B1 (en) 2005-04-07 2013-10-02 The Trustees of The University of Pennsylvania Method of increasing the function of an AAV vector
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
WO2010005533A2 (en) 2008-06-30 2010-01-14 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
US20110305772A1 (en) 2009-02-26 2011-12-15 The Johns Hopkins University Compositions and methods for ex vivo hepatic nucleic acid delivery
RU2444977C2 (ru) 2009-08-03 2012-03-20 Федеральное государственное учреждение "МОСКОВСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ ИМЕНИ ГЕЛЬМГОЛЬЦА ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ВЫСОКОТЕХНОЛОГИЧНОЙ МЕДИЦИНСКОЙ ПОМОЩИ" Способ диагностики ахроматопсии
US20120172419A1 (en) * 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
SG183929A1 (en) 2010-03-29 2012-10-30 Univ Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP2661494B1 (en) * 2011-01-07 2019-06-12 Applied Genetic Technologies Corporation Promoters, expression cassettes and vectors for use treating achromatopsia and other diseases
GB201103062D0 (en) 2011-02-22 2011-04-06 Isis Innovation Method
US9249425B2 (en) 2011-05-16 2016-02-02 The Trustees Of The University Of Pennslyvania Proviral plasmids and production of recombinant adeno-associated virus
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
WO2013063601A1 (en) 2011-10-28 2013-05-02 University Of Florida Research Foundation, Inc. Chimeric promoter for cone photoreceptor targeted gene therapy
US20140314740A1 (en) 2011-12-09 2014-10-23 The Johns Hopkins University Compositions and methods for the prevention or treatment of diabetic complications
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
NZ704275A (en) 2012-07-11 2016-09-30 Univ Florida Aav-mediated gene therapy for rpgr x-linked retinal degeneration
CA2881081C (en) 2012-08-08 2017-04-18 Nihon Parkerizing Co., Ltd. Metal surface treatment liquid, surface treatment method for metal base, and metal base obtained thereby
EP2954051B1 (en) 2013-02-08 2019-03-27 The Trustees Of The University Of Pennsylvania Modified aav8 capsid for gene transfer for retinal therapies
DK2986635T3 (en) 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
WO2014186160A1 (en) 2013-05-16 2014-11-20 Applied Genetic Technologies Corporation Promoters, expression cassettes, vectors, kits, and methods for the threatment of achromatopsia and other diseases
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
JP6689249B2 (ja) 2014-03-17 2020-05-20 アドヴェラム バイオテクノロジーズ， インコーポレイテッド 錐体細胞における増強された遺伝子発現のための組成物および方法
AU2015247777B2 (en) 2014-04-15 2019-03-21 Beacon Therapeutics Limited Codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR)
US20160206704A1 (en) 2015-01-16 2016-07-21 Isis Innovation Limited Method
EP3795180B1 (en) * 2015-12-14 2025-11-05 The Trustees of The University of Pennsylvania Gene therapy for ocular disorders

Also Published As

Publication number Publication date
CN109069668A (zh) 2018-12-21
MX2018007230A (es) 2018-11-09
CA3008264A1 (en) 2017-06-22
US20200061209A1 (en) 2020-02-27
US12403204B2 (en) 2025-09-02
US20210330816A1 (en) 2021-10-28
US11090392B2 (en) 2021-08-17
EP3795180A1 (en) 2021-03-24
EP3389724B1 (en) 2020-07-01
RU2018125468A3 (es) 2020-10-22
WO2017106202A2 (en) 2017-06-22
JP2022088656A (ja) 2022-06-14
JP7057281B2 (ja) 2022-04-19
BR112018011838A2 (pt) 2018-12-04
CN109069668B (zh) 2023-04-18
AU2016370487A1 (en) 2018-07-05
AU2016370487B2 (en) 2021-08-05
AU2016370487C1 (en) 2022-03-03
RU2018125468A (ru) 2020-01-16
KR20180099719A (ko) 2018-09-05
EP3795180B1 (en) 2025-11-05
ES2826384T3 (es) 2021-05-18
JP2019502378A (ja) 2019-01-31
EP3389724A2 (en) 2018-10-24
RU2762747C2 (ru) 2021-12-22
WO2017106202A3 (en) 2017-08-31
HK1258518A1 (zh) 2019-11-15

Similar Documents

Publication Publication Date Title
MX2022010959A (es) Terapia genica para trastornos oculares.
IL278058A (en) Oligonucleotide compounds of 5-cap-tetranucleotide or higher and their uses in RNA production, protein expression and medicine
IL280652A (en) Nucleic acid molecules and their use for non-viral gene therapy
MX383142B (es) Composiciones que comprenden polipéptidos que tienen actividad xilanasa y polipéptidos que tienen actividad arabinofuranosidasa.
IL252917A0 (en) Vectors and vectors for gene therapy for use in the treatment of Wilson's disease
SI3233129T1 (sl) Konstrukti nukleinske kisline in vektorji genske terapije za uporabo pri zdravljenju Wilsonove bolezni in drugih stanj
IL271389A (en) Targeted non-viral dna insertions
EP3440205A4 (en) NONINVASIVE DIAGNOSIS BY SEQUENCING OF 5-HYDROXYMETHYLATED CELL-FREE DNA
EP3741849A3 (en) Protease variants and polynucleotides encoding same
WO2014179331A3 (en) Devices, systems and methods for optogenetic modulation of action potentials in target cells
HK1256909A1 (zh) Glp-1和其在用於治疗代谢疾病的组合物中的用途
PH12018500568B1 (en) Antisense nucleic acid
CY1123793T1 (el) Γονιδιακη θεραπεια rpgr για μελαγχρωστικη αμφιβληστροειδοπαθεια
GB2571603B (en) Hair treatment agent with anti-dandruff action
HK1257024A1 (zh) 用於治疗伴侣动物的aav-epo
GB201513098D0 (en) Catalytically active protein aggregates and methods for producing the same
MX2018013875A (es) Composiciones que comprenden polipeptidos que tienen actividad galactanasa y polipeptidos que tienen actividad beta-galactosidasa.
PT3253781T (pt) Proteína dkk2 modificada, ácido nucleico que codifica a mesma, método de preparação da mesma e uso da mesma
IL274363A (en) Use of a specific siRNA against protein S for the treatment of hemophilia
MX2018014434A (es) Composiciones que comprenden polipeptidos que tienen actividad galactanasa y polipeptidos que tienen actividad beta-galactosidasa.
EP3308789A4 (en) NUCLEIC ACID-FREEZING CARRIER, NUCLEIC ACID-FREEZING KIT, AND NUCLEIC ACID-FREEZING METHOD
王剑 FE 70-200mm F4 G OSS
Appannacharya Sri Jagannatadasara Kritigalu-K Appannacharya
Appannacharya Sri Vittaladaasara Kritigalu-K Appannacharya
Atkinson The chemistry of saké-brewing